Home > Healthcare > Medical Devices > Diagnostic Devices > legionella testing market
Get a free sample of Legionella Testing Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Legionella Testing Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Based on test type, the market is segmented into culture methods, urinary antigen test (UAT), serology, direct fluorescent antibody test (DFA), polymerase chain reaction (PCR) testing, and other test types. The culture methods segment is estimated to account for USD 200.8 million by 2032.
Based on application the legionella testing market is segmented into water testing, invitro diagnostics (IVD)testing [which is estimated to reach USD 141 billion by 2032], and other applications. The water testing segment accounted for USD 193.6 million in 2023.
Based on end-use, the legionella testing market is segmented into hospital and clinics, water treatment plants, diagnostic laboratories, and other end-users. The water treatment plants segment held the largest business share of 45.3% in 2023. This substantial share can be attributed to the critical role that water treatment plants play in ensuring the safety and purity of water supplies by treating water from various sources.
In 2023, North America held a significant business share of 40.6% in the global legionella testing market and is predicted to witness substantial market growth over the analysis timeline.
Water legionella testing industry accounted for USD 193.6 million in 2023 and will grow significantly through 2032 attributed to the heightened awareness surrounding legionella-related illnesses, such as legionnaires' disease.
Global legionella testing industry was valued at USD 316.8 million in 2023 and is estimated to reach over USD 659.4 million by 2032 attributed to the increasing prevalence of pneumonia and legionella-related illnesses.
Abbott Laboratories, Becton, Dickinson & Company, Biomerieux, Bio-Rad Laboratories Inc., Danaher Corporation, IDEXX Laboratories Inc, Merck KGaA, Pro-lab Diagnostics Inc., QIAGEN N.V., and Thermo Fisher Scientific Inc.
North America recorded 40.6% of the legionella testing industry share in 2023 and is predicted to witness substantial growth through 2032 as the region has a robust healthcare infrastructure and regulatory framework that emphasizes the importance of legionella testing for public health and safety.